Literature DB >> 21986855

Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Dorra Bouzid1, Samy Haddouk, Ali Amouri, Youssef Ben Hadj Hmida, Nabil Tahri, Hatem Masmoudi.   

Abstract

We evaluated the combined use of different fixatives for the identification of atypical perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in patients with inflammatory bowel diseases (IBD) by indirect immunofluorescence (IIF). Sera from 59 ulcerative colitis (UC) and 37 Crohn's disease (CD) patients, and from 64 healthy controls were studied. The IIF on ethanol-, formalin-, and methanol-fixed neutrophils was used for the detection of ANCA. Enzyme linked immunosorbant assay (ELISA) was performed to identify the antigens recognized by ANCA. ANCAs were present in 35 of 59 (59.3%) UC patients and in 10 of 37 (27.02%) CD patients. Atypical p-ANCA positivity was strongly associated with UC disease (44.1% in UC vs. 8.1% in CD; p = 0.0002). The combined application of different fixatives contributed to make easy the differentiation between typical p-ANCA and atypical p-ANCA. Atypical p-ANCA determination appears to be a useful parameter for the distinction between UC and CD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21986855     DOI: 10.1007/s12664-011-0127-3

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  12 in total

1.  Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives.

Authors:  A Radice; M Vecchi; M B Bianchi; R A Sinico
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 3.  Inflammatory bowel disease: etiology and pathogenesis.

Authors:  C Fiocchi
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

4.  Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease.

Authors:  H Freeman; B Roeck; D Devine; C Carter
Journal:  Can J Gastroenterol       Date:  1997-04       Impact factor: 3.522

Review 5.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Authors:  J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik
Journal:  Am J Clin Pathol       Date:  1999-04       Impact factor: 2.493

6.  Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens.

Authors:  K Sugi; O Saitoh; R Matsuse; K Tabata; K Uchida; K Kojima; K Nakagawa; S Tanaka; T Teranishi; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

7.  Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy.

Authors:  B Terjung; H J Worman; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

8.  Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis.

Authors:  Vishal Anand; Anthony S Russell; Ross Tsuyuki; Richard Fedorak
Journal:  Can J Gastroenterol       Date:  2008-01       Impact factor: 3.522

9.  Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease.

Authors:  Frank H Klebl; Frauke Bataille; Claudia R Bertea; Hans Herfarth; Ferdinand Hofstädter; Jürgen Schölmerich; Gerhard Rogler
Journal:  Inflamm Bowel Dis       Date:  2003-09       Impact factor: 5.325

10.  Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study.

Authors:  S Desplat-Jégo; C Johanet; A Escande; J Goetz; N Fabien; N Olsson; E Ballot; J Sarles; J J Baudon; J C Grimaud; M Veyrac; P Chamouard; R L Humbel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

View more
  3 in total

Review 1.  Anti-neutrophil cytoplasmic antibodies and their clinical significance.

Authors:  Supaporn Suwanchote; Muanpetch Rachayon; Pongsawat Rodsaward; Jongkonnee Wongpiyabovorn; Tawatchai Deekajorndech; Helen L Wright; Steven W Edwards; Michael W Beresford; Pawinee Rerknimitr; Direkrit Chiewchengchol
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

2.  Diagnostic Value of ASCA and Atypical p-ANCA in Differential Diagnosis of Inflammatory Bowel Disease.

Authors:  Ali Mokhtarifar; Azita Ganji; Mohsen Sadrneshin; Ali Bahari; Abbas Esmaeilzadeh; Kamran Ghafarzadegan; Shafagh Nikpour
Journal:  Middle East J Dig Dis       Date:  2013-04

3.  ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation.

Authors:  Naim Abu-Freha; Wafi Badarna; Ina Sigal-Batikoff; Muhammad Abu Tailakh; Ohad Etzion; Jaber Elkrinawi; Arik Segal; Alex Mushkalo; Alex Fich
Journal:  BMC Gastroenterol       Date:  2018-10-20       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.